keyword
MENU ▼
Read by QxMD icon Read
search

Addiction ketamine

keyword
https://www.readbyqxmd.com/read/27888525/breaking-sad-unleashing-the-breakthrough-potential-of-ketamine-s-rapid-antidepressant-effects
#1
David Feifel
Preclinical Research The surprising results of a small clinical trial on the effects of low dose ketamine, a 65-year old anesthetic drug that is also used off-label for chronic pain and recreationally as a club drug, in eight depressed subjects unleashed the most significant advance in antidepressant drug development in decades. That study and subsequent ones have demonstrated that low dose, infused ketamine is able to induce a remission of depression in patients who have failed conventional medications, within 24 h...
November 26, 2016: Drug Development Research
https://www.readbyqxmd.com/read/27842789/ketamine-a-cause-of-urinary-tract-dysfunction
#2
REVIEW
Frank Anthony Myers, Martin H Bluth, Wellman W Cheung
Drug addiction as a result of improper use of prescribed and illicit use has been on the increase globally. The effects of such use have implications in the urologic disease space. To this end, Ketamine has been reported to affect urologic function, causing a number of voiding symptoms. It may also confound the differential diagnosis of urologic diseases, such as interstitial cystitis, among others.
December 2016: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/27836553/how-much-alcohol-is-in-ketamine-s-antidepressant-action
#3
REVIEW
Udo Bonnet
Ketamine is approved to start and maintain anaesthesia or analgesia. Ketamine is also known to be neurotoxic and an old drug of abuse. Numerous studies have proven a rapid and strong antidepressant response (AR) following parenteral sub-anaesthetic ketamine doses when applied the first time to patients with treatment resistant unipolar or bipolar major depression. This rapid and robust AR is encouraging, though short-lived (usually up to seven days). There is growing evidence that repeated und escalating ketamine administrations exert longer-lasting AR than single infusions...
November 8, 2016: Life Sciences
https://www.readbyqxmd.com/read/27832755/experience-of-the-use-of-ketamine-to-manage-opioid-withdrawal-in-an-addicted-woman-a-case-report
#4
Laurence Lalanne, Chloe Nicot, Jean-Philippe Lang, Gilles Bertschy, Eric Salvat
BACKGROUND: Opioids are good painkillers, but many patients treated with opioids as painkillers developed a secondary addiction. These patients need to stop misusing opioids, but the mild-to-severe clinical symptoms associated with opioid withdrawal risk increasing their existing pain. In such cases, ketamine, which is used by anaesthetists and pain physicians to reduce opioid medication, may be an effective agent for managing opioid withdrawal. CASE PRESENTATION: We describe the case of a woman who developed a severe secondary addiction to opioids in the context of lombo-sciatic pain...
November 10, 2016: BMC Psychiatry
https://www.readbyqxmd.com/read/27713001/levo-tetrahydropalmatine-inhibits-the-acquisition-of-ketamine-induced-conditioned-place-preference-by-regulating-the-expression-of-erk-and-creb-phosphorylation-in-rats
#5
Yan Du, Li Du, Jie Cao, Christian Hölscher, Yongming Feng, Hongliang Su, Yujin Wang, Ke-Ming Yun
Levo-tetrahydropalmatine (l-THP) is an alkaloid purified from the Chinese herbs Corydalis and Stephania and has been used in many traditional Chinese herbal preparations for its sedative, analgesic and hypnotic properties. Previous studies demonstrated that l-THP has antagonistic activity on dopamine receptors; thus, it may have potential therapeutic effects on drug abuse. However, whether l-THP affects ketamine-induced conditioned place preference (CPP) remains unclear. Therefore, the present study was designed to evaluate the effects of l-THP on the rewarding behavior of ketamine through CPP...
October 3, 2016: Behavioural Brain Research
https://www.readbyqxmd.com/read/27649773/subanesthetic-ketamine-decreases-the-incentive-motivational-value-of-reward-related-cues
#6
Christopher J Fitzpatrick, Jonathan D Morrow
The attribution of incentive-motivational value to reward-related cues contributes to cue-induced craving and relapse in addicted patients. Recently, it was demonstrated that subanesthetic ketamine increases motivation to quit and decreases cue-induced craving in cocaine-dependent individuals. Although the underlying mechanism of this effect is currently unknown, one possibility is that subanesthetic ketamine decreases the incentive-motivational value of reward-related cues. In the present study, we used a Pavlovian conditioned approach procedure to identify sign-trackers, rats that attribute incentive-motivational value to reward-related cues, and goal-trackers, rats that assign only predictive value to reward-related cues...
September 20, 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27376671/the-similarities-and-differences-in-impulsivity-and-cognitive-ability-among-ketamine-methadone-and-non-drug-users
#7
Hong Zeng, Dequan Su, Xing Jiang, Liang Zhu, Haosheng Ye
The study aimed to identify similarities and differences among ketamine, methadone users, and non-drug-using controls, on impulsivity, antisocial personality, and related cognitive abilities. A case-control observational design was used to compare the impulsivity and cognitive function of ketamine users (n = 51), methadone users (n=59), and controls (n=60). Antisocial personality traits and emotion states were also measured. One-way ANOVAs and planned post hoc pair-wise tests were used to analyze the data. Compared to non-drug-using controls, ketamine and methadone users had elevated scores on BIS and Pd scale of the MMPI, poorer performance on 2-back task, Stop-signal task, and Stroop test...
September 30, 2016: Psychiatry Research
https://www.readbyqxmd.com/read/27341080/the-abuse-liability-of-the-nmda-receptor-antagonist-benzodiazepine-tiletamine-zolazepam-combination-evidence-from-clinical-case-reports-and-preclinical-studies
#8
REVIEW
June Bryan de la Peña, Jae Hoon Cheong
The tiletamine-zolazepam (TZ) combination is an anaesthetic drug commonly used in veterinary medicine. It is an equal amount combination of tiletamine, a dissociative anaesthetic pharmacologically classified as an N-methyl-D-aspartate (NMDA) receptor antagonist, and zolazepam, a benzodiazepine tranquilizer. There are concerns regarding the safety profile of this drug combination due to incidents of human misuse/abuse. In this paper, we discuss the abuse liability of this drug combination based on currently available scientific evidence...
August 2016: Drug Testing and Analysis
https://www.readbyqxmd.com/read/27321205/neural-response-differences-in-the-rat-primary-auditory-cortex-under-anesthesia-with-ketamine-versus-the-mixture-of-medetomidine-midazolam-and-butorphanol
#9
Hisayuki Osanai, Takashi Tateno
Anesthesia affects central auditory processing. However, it is unclear to what extent the choice of anesthetic agent affects neural responses to sound stimulation. A mixture of three anesthetics (medetomidine, midazolam and butorphanol; MMB) was recently developed as an alternative to ketamine owing to the latter's addictive potential, yet the effect of this combination of anesthetics on neural responses is not known. Here, we compared the spontaneous activity, tuning properties and temporal responses of primary auditory cortical neurons under these two anesthetic conditions, using electrophysiological and flavoprotein autofluorescence imaging methods...
September 2016: Hearing Research
https://www.readbyqxmd.com/read/27261367/ketamine-abuse-potential-and-use-disorder
#10
Yu Liu, Deyong Lin, Boliang Wu, Wenhua Zhou
Ketamine is a noncompetitive antagonist of N-methyl-d-asparate (NMDA) receptor and has been long used as an anesthetic agent in humans and veterinary medicine. The present article reviews the epidemiology, pharmacology, neurochemistry, and treatment of ketamine abuse. Ketamine has a unique mood controlling property and a number of studies have demonstrated a significant and rapid antidepressant effect of ketamine. However, the therapeutic value of ketamine to treat psychiatric disorders faces a major challenge that ketamine also owns significant reinforcing and toxic effects...
September 2016: Brain Research Bulletin
https://www.readbyqxmd.com/read/27020786/the-ketamine-like-compound-methoxetamine-substitutes-for-ketamine-in-the-self-administration-paradigm-and-enhances-mesolimbic-dopaminergic-transmission
#11
Anna Mutti, Sonia Aroni, Paola Fadda, Laura Padovani, Laura Mancini, Roberto Collu, Anna Lisa Muntoni, Liana Fattore, Cristiano Chiamulera
RATIONALE: Recently, an increasing number of emergency cases due to a novel ketamine-like drug, methoxetamine (MXE), were reported in several countries. However, very little is known about the neuropsychopharmacological and reinforcing profile of this compound. OBJECTIVES: Our study aims to investigate the effects of MXE on self-administration (SA) behaviour in comparison to ketamine and on dopaminergic transmission. METHODS: A SA substitution study was performed in male rats trained to intravenously (IV) self-administer ketamine...
June 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27002655/exploring-hallucinogen-pharmacology-and-psychedelic-medicine-with-zebrafish-models
#12
Evan J Kyzar, Allan V Kalueff
After decades of sociopolitical obstacles, the field of psychiatry is experiencing a revived interest in the use of hallucinogenic agents to treat brain disorders. Along with the use of ketamine for depression, recent pilot studies have highlighted the efficacy of classic serotonergic hallucinogens, such as lysergic acid diethylamide and psilocybin, in treating addiction, post-traumatic stress disorder, and anxiety. However, many basic pharmacological and toxicological questions remain unanswered with regard to these compounds...
October 2016: Zebrafish
https://www.readbyqxmd.com/read/26982922/an-ethical-exploration-of-barriers-to-research-on-controlled-drugs
#13
Michael H Andreae, Evelyn Rhodes, Tyler Bourgoise, George M Carter, Robert S White, Debbie Indyk, Henry Sacks, Rosamond Rhodes
We examine the ethical, social, and regulatory barriers that may hinder research on therapeutic potential of certain controversial controlled substances like marijuana, heroin, or ketamine. Hazards for individuals and society and potential adverse effects on communities may be good reasons for limiting access and justify careful monitoring of these substances. Overly strict regulations, fear of legal consequences, stigma associated with abuse and populations using illicit drugs, and lack of funding may, however, limit research on their considerable therapeutic potential...
2016: American Journal of Bioethics: AJOB
https://www.readbyqxmd.com/read/26879874/new-pain-management-options-for-the-surgical-patient-on-methadone-and-buprenorphine
#14
Sudipta Sen, Sailesh Arulkumar, Elyse M Cornett, Julie A Gayle, Ronda R Flower, Charles J Fox, Alan D Kaye
Perioperative management of patients receiving opioid addiction therapy presents a unique challenge for the anesthesiologist. The goal of pain management in this patient population is to effectively manage postoperative pain, to improve patient satisfaction and outcomes, and to reduce the cost of health care. Multimodal analgesics, including nonsteroid anti-inflammatory drugs, intravenous acetaminophen, gabapentanoid agents, and low-dose ketamine infusions, have been used to improve postoperative pain and to reduce postoperative opioid use...
March 2016: Current Pain and Headache Reports
https://www.readbyqxmd.com/read/26866970/the-ketamine-analogue-methoxetamine-generalizes-to-ketamine-discriminative-stimulus-in-rats
#15
Cristiano Chiamulera, Federica Armani, Anna Mutti, Liana Fattore
Methoxetamine (MXE) is a chemical analogue of ketamine. Originally proposed as a ketamine-like fast-acting antidepressant, owing to similar N-methyl-D-aspartate blocker properties, it is now scheduled for reports of hallucinations and psychosis similar to ketamine and lysergic acid. As little is known about the addictive properties of MXE, the aim of this study was to investigate the similarity between discriminative stimuli of MXE and ketamine, as well as to provide data and protocols that could be used in the future for the characterization of novel ketamine-like drugs...
April 2016: Behavioural Pharmacology
https://www.readbyqxmd.com/read/26849894/should-ketamine-be-used-for-the-clinical-treatment-of-depression
#16
Shalini Arunogiri, Nicholas A Keks, Judy Hope
OBJECTIVE: There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression. CONCLUSIONS: Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years. However, there remain many unanswered questions regarding its effectiveness, safety, and the route, dose and regimen for repeated administration...
August 2016: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/26632202/potential-benefit-of-lamotrigine-in-managing-ketamine-use-disorder
#17
Ming-Chyi Huang, Lian-Yu Chen, Chih-Ken Chen, Shih-Ku Lin
Ketamine is an anesthetic derivative of phencyclidine (PCP; 'Angel dust') with dissociative, analgesic and psychedelic properties. Ketamine has become a popular recreational drug of abuse in many parts of the world in recent years. The preclinical studies demonstrate the reinforcing effects of ketamine and long-term ketamine abuse induces a delayed and persistent upregulation of dopamine system. In humans, there have been concerns about its liability to development of addiction. The dilemma of mental professionals in managing the treatment-seeking ketamine abusers comes from a lack of effective pharmacotherapy...
February 2016: Medical Hypotheses
https://www.readbyqxmd.com/read/26317449/long-term-ketamine-self-injections-in-major-depressive-disorder-focus-on-tolerance-in-ketamine-s-antidepressant-response-and-the-development-of-ketamine-addiction
#18
Udo Bonnet
Sub-anaesthetic ketamine is of special interest for depression research due to its rapid and potent but short-lived antidepressant response (after-effect). The presented case is the first one in the literature which deals in detail with the transfer from ketamine's antidepressant action to ketamine addiction. A 50-year-old anaesthetic nurse, who had never been treated with antidepressants before, started with self-injecting ketamine racemate 50 mg IM once a week to cope with her major depression. She continuously stole ketamine from hospital stocks...
September 2015: Journal of Psychoactive Drugs
https://www.readbyqxmd.com/read/26129677/withdrawal-from-acute-amphetamine-induces-an-amygdala-driven-attenuation-of-dopamine-neuron-activity-reversal-by-ketamine
#19
Pauline Belujon, Nicole L Jakobowski, Hannah K Dollish, Anthony A Grace
Drug addiction is a chronic disorder characterized by a cycle composed of drug seeking, intoxication with drug taking and withdrawal associated with negative affect. Numerous studies have examined withdrawal/negative affect after chronic use; however, very few have examined the effect of acute administration on the negative affective state after acute drug withdrawal. One dose of amphetamine was injected into Sprague-Dawley rats. Despair behavior using the modified forced swim test (FST) and dopamine (DA) activity in the ventral tegmental area using in vivo electrophysiological recordings were studied 18, 48 and 72 h after injection of amphetamine...
January 2016: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/26070759/-addicted-to-euphoria-the-history-clinical-presentation-and-management-of-party-drug-misuse
#20
REVIEW
Jenny Bearn, Matthew O'Brien
Eating, drinking, sexual activity, and parenting invoke pleasure, an emotion that promotes repetition of these behaviors, are essential for survival. Euphoria, a feeling or state of intense excitement and happiness, is an amplification of pleasure, aspired to one's essential biological needs that are satisfied. People use party drugs as a shortcut to euphoria. Ecstasy (3,4-methylenedioxymethamphetamine), γ-hydroxybutyric acid, and ketamine fall under the umbrella of the term "party drugs," each with differing neuropharmacological and physiological actions...
2015: International Review of Neurobiology
keyword
keyword
44003
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"